羟丁酸
多汗症
医学
汗水
麻醉
离子导入
耐火材料(行星科学)
皮肤病科
泌尿科
内科学
物理
替代医学
病理
天体生物学
膀胱过度活动
放射科
作者
Céline Try,R Messikh,A Elkhyat,F. Aubin,R Humbert
出处
期刊:PubMed
日期:2012-10-01
卷期号:67 (10): 520-6
被引量:20
摘要
Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment. Nine patients were treated for primary hyperhidrosis resistant to conventional therapies with oxybutynin between January to May 2010. The treatment was progressively increased at 7.5 mg per day. Oxybutynin efficacy was evaluated by iodine starch test and biometrological measurements at 2 and 4 weeks of treatment. Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI) were obtained for each patient. The means of HDSS and DLQI were respectively 3.2 +/- 0.7 and 17.0 +/- 5.1 before treatment and were 1.8 +/- 0.4 and 4.6 +/- 4.4 at 4 weeks of treatment. Oxybutynin at 7.5 mg per day significantly decreased intensity and area of sweat for palms but not for soles. Trans Epidermal Water Loss, conductance, pH and Skin temperature were modified with treatment. Oxybutynin at 7.5 mg per day has improved patient's quality of life. Efficiency of oxybutynin in primary palmar hyperhidrosis was proved by biometrological measurements and iodine starch test.
科研通智能强力驱动
Strongly Powered by AbleSci AI